Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Effects of growth hormone administration for 6 months on bone turnover and bone marrow fat in obese premenopausal women.

Bredella MA, Gerweck AV, Barber LA, Breggia A, Rosen CJ, Torriani M, Miller KK.

Bone. 2014 May;62:29-35. doi: 10.1016/j.bone.2014.01.022. Epub 2014 Feb 5.

2.

Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial.

Bredella MA, Lin E, Brick DJ, Gerweck AV, Harrington LM, Torriani M, Thomas BJ, Schoenfeld DA, Breggia A, Rosen CJ, Hemphill LC, Wu Z, Rifai N, Utz AL, Miller KK.

Eur J Endocrinol. 2012 Apr;166(4):601-11. doi: 10.1530/EJE-11-1068. Epub 2012 Jan 24.

3.

Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity.

Bredella MA, Gerweck AV, Lin E, Landa MG, Torriani M, Schoenfeld DA, Hemphill LC, Miller KK.

J Clin Endocrinol Metab. 2013 Sep;98(9):3864-72. doi: 10.1210/jc.2013-2063. Epub 2013 Jul 3.

4.

Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults--an 18-month randomised, placebo-controlled, double blinded trial.

Sneppen SB, Hoeck HC, Kollerup G, Sørensen OH, Laurberg P, Feldt-Rasmussen U.

Eur J Endocrinol. 2002 Feb;146(2):187-95.

5.

Effects of growth hormone withdrawal in obese premenopausal women.

Lin E, Bredella MA, Gerweck AV, Landa M, Schoenfeld D, Utz AL, Miller KK.

Clin Endocrinol (Oxf). 2013 Jun;78(6):914-9. doi: 10.1111/cen.12102.

6.

Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-1 in obese women.

Bredella MA, Torriani M, Ghomi RH, Thomas BJ, Brick DJ, Gerweck AV, Rosen CJ, Klibanski A, Miller KK.

Obesity (Silver Spring). 2011 Jan;19(1):49-53. doi: 10.1038/oby.2010.106. Epub 2010 May 13.

7.

Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women.

Ghiron LJ, Thompson JL, Holloway L, Hintz RL, Butterfield GE, Hoffman AR, Marcus R.

J Bone Miner Res. 1995 Dec;10(12):1844-52.

PMID:
8619364
8.

Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.

Fernholm R, Bramnert M, Hägg E, Hilding A, Baylink DJ, Mohan S, Thorén M.

J Clin Endocrinol Metab. 2000 Nov;85(11):4104-12.

PMID:
11095440
9.

Metabolic effects of biosynthetic growth hormone treatment in severely energy-restricted obese women.

Tagliaferri M, Scacchi M, Pincelli AI, Berselli ME, Silvestri P, Montesano A, Ortolani S, Dubini A, Cavagnini F.

Int J Obes Relat Metab Disord. 1998 Sep;22(9):836-41.

10.

Short-Term Effect of Estrogen on Human Bone Marrow Fat.

Limonard EJ, Veldhuis-Vlug AG, van Dussen L, Runge JH, Tanck MW, Endert E, Heijboer AC, Fliers E, Hollak CE, Akkerman EM, Bisschop PH.

J Bone Miner Res. 2015 Nov;30(11):2058-66. doi: 10.1002/jbmr.2557. Epub 2015 Jul 14.

11.

Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women.

Holloway L, Butterfield G, Hintz RL, Gesundheit N, Marcus R.

J Clin Endocrinol Metab. 1994 Aug;79(2):470-9.

PMID:
7519191
12.

Determinants of bone mineral density in obese premenopausal women.

Bredella MA, Torriani M, Ghomi RH, Thomas BJ, Brick DJ, Gerweck AV, Harrington LM, Breggia A, Rosen CJ, Miller KK.

Bone. 2011 Apr 1;48(4):748-54. doi: 10.1016/j.bone.2010.12.011. Epub 2010 Dec 30.

13.

Effect of zoledronic acid on vertebral marrow adiposity in postmenopausal osteoporosis assessed by MR spectroscopy.

Yang Y, Luo X, Yan F, Jiang Z, Li Y, Fang C, Shen J.

Skeletal Radiol. 2015 Oct;44(10):1499-505. doi: 10.1007/s00256-015-2200-y. Epub 2015 Jul 1.

PMID:
26130070
14.

Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.

Cohen A, Stein EM, Recker RR, Lappe JM, Dempster DW, Zhou H, Cremers S, McMahon DJ, Nickolas TL, Müller R, Zwahlen A, Young P, Stubby J, Shane E.

J Clin Endocrinol Metab. 2013 May;98(5):1971-81. doi: 10.1210/jc.2013-1172. Epub 2013 Mar 29.

15.

Growth hormone is positively associated with surrogate markers of bone turnover during puberty.

Russell M, Breggia A, Mendes N, Klibanski A, Misra M.

Clin Endocrinol (Oxf). 2011 Oct;75(4):482-8. doi: 10.1111/j.1365-2265.2011.04088.x.

16.

Effect of growth hormone on body composition and visceral adiposity in middle-aged men with visceral obesity.

Pasarica M, Zachwieja JJ, Dejonge L, Redman S, Smith SR.

J Clin Endocrinol Metab. 2007 Nov;92(11):4265-70. Epub 2007 Sep 4.

PMID:
17785361
17.

Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.

Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA.

J Clin Endocrinol Metab. 1998 Feb;83(2):362-9.

PMID:
9467542
18.

Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa.

Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A.

J Clin Endocrinol Metab. 1996 Nov;81(11):3864-70.

PMID:
8923830
19.

Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.

Amato G, Mazziotti G, Di Somma C, Lalli E, De Felice G, Conte M, Rotondi M, Pietrosante M, Lombardi G, Bellastella A, Carella C, Colao A.

J Clin Endocrinol Metab. 2000 Oct;85(10):3720-5.

PMID:
11061530
20.

Insulin-like growth factor-1 is associated with bone formation markers, PTH and bone mineral density in healthy premenopausal women.

Adami S, Zivelonghi A, Braga V, Fracassi E, Gatti D, Rossini M, Ulivieri FM, Viapiana O.

Bone. 2010 Jan;46(1):244-7. doi: 10.1016/j.bone.2009.10.011. Epub 2009 Oct 21.

PMID:
19853071

Supplemental Content

Support Center